The ASCO Post

🆕 meta-analysis data reinforce long-term value of ovarian function suppression in premenopausal ER+ early #breastcancer. Among women <45 years: ☑️️ Reduced recurrence ☑️ Reduced breast cancer mortality 🔹Early Breast Cancer Trialists’ Collaborative Group ascopost.com/news/may-2026/…

🖥️ #ASCOAI: As #AI-generated deepfakes become more sophisticated, the @AmerMedicalAssn is calling for stronger protections around physician identity, consent, and transparency to help prevent medical misinformation. Learn more: ascoai.org/articles/2026/…

🧬 New data suggest monitoring CEA, CA19-9, and CA125 markers before/after cytoreductive surgery may stratify relapse risk in patients with appendiceal adenocarcinoma, and identify needs for additional therapy. 👨‍⚕️ John Paul Shen, MD, of @UTMDAnderson 🔗 ascopost.com/news/may-2026/…

After 9 lines of therapy, 4 clinical trials, radiation, major surgery, and metastatic progression, Bill Thach continues living with advanced neuroendocrine carcinoma of the rectum while navigating each new treatment option. Read this powerful perspective: ascopost.com/issues/may-10-…

🆕 @ASCO guidance highlights how molecular testing is reshaping #thyroidcancer management. The guideline addresses sequencing, toxicity, and integration of targeted therapies across differentiated, anaplastic, and medullary thyroid cancers. Learn more ➡️ ascopost.com/issues/may-10-…

🫂 A powerful reminder in oncology care: communication is care In this thoughtful commentary from Dr. Muhammad Rafiqul Islam, he details how trust, listening, empathy, and patient perception influence the experience and effectiveness of oncology care. 🔗 ascopost.com/issues/may-10-…

🖥️ #ASCOAI: Agentic #AI may help drive new cancer developments, guide treatment decisions. The SPARK framework autonomously generated biomarker hypotheses, validated prognostic markers, & uncovered new insights into tumor evolution in 5 cancer types. 🔗 ascoai.org/articles/2026/…

⏳Long-term remission in metastatic #pancreaticcancer remains rare. In a rucaparib maintenance study, 7 patients with BRCA/PALB2-altered PDAC remained progression free for >5.5 years ➡️ far exceeding historical expectations. 👩‍⚕️ @KReissMD | @JAMAOncol 🔗 ascopost.com/news/may-2026/…

🚨 #FDAApproval: The @US_FDA approved zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable, or metastatic NRG1 fusion–positive #cholangiocarcinoma following prior systemic therapy. Approval based on findings from the phase II eNRGy trial. ascopost.com/news/may-2026/…

🫀In a cohort of patients with #melanoma on BRAF/MEK inhibitors: • 46% developed hypertension • 46% developed treatment-related cardiac dysfunction ☑️ Most cases mild; moderate/severe events appeared as early as 4 weeks 🔹 Glen et al | @JACCJournals ascopost.com/issues/may-10-…

🫁 Phase III SKYSCRAPER-06 showed no survival benefit with tiragolumab + atezolizumab + chemotherapy in advanced nonsquamous #NSCLC. ➡️ Grade 3/4 AEs were similar between arms, but efficacy endpoints were not met. 🔸 Mark A. Socinski, MD | @JAMAOncol 🔗 ascopost.com/news/may-2026/…

🖥️ #AI continues moving from research to real-world oncology applications This week’s #ASCOAI News Brief covers: 🔹Pancreatic cancer detection advancements 🔹 FDA clinical trial acceleration 🔹 AI-supported mammography workflows 🎥 Watch the weekly brief: ascoai.org/videos/weekly-…

Highlights from #ASBrS26 emphasize where #breastcancer care is heading: • More surgical de-escalation • Greater focus on recovery and function • Expanded personalization after neoadjuvant therapy • Conservation in younger patients Learn more ➡️ ascopost.com/issues/may-10-…

🩸 Leukemia care has transformed in 50 years From TKIs in CML to bispecifics, CAR-T, and MRD-guided therapy in ALL/AML, outcomes once thought impossible are becoming reality. Read this insightful perspective from @DrHKantarjian of @UTMDAnderson: ascopost.com/issues/may-10-…

🖥️ #ASCOAI: A new AI framework may help detect #pancreaticcancer years earlier than current clinical practice. REDMOD identified stage 0 pancreatic ductal adenocarcinoma with nearly double the sensitivity of radiologists and up to 3 years before diagnosis. ascoai.org/articles/2026/…

🧬 ctDNA in early #breastcancer is promising, but not yet ready for clinical use Experts emphasize that no interventional trial has shown ctDNA-guided treatment leads to improved outcomes. 🗣️ Presenter Heather A. Parsons, MD, MPH at #MBCC2026 Read more 👉 ascopost.com/news/may-2026/…

AI is accelerating the future of #PrecisionOncology; from smarter therapy matching to improved clinical trial design and personalized #cancercare. Join @VivekSubbiah and @chadinabhan as they discuss where #AI is making the biggest impact in oncology today. ascoai.broadcastmed.io/live/1/page/1

🆕 The first May issue of The ASCO Post is LIVE, featuring practice-changing data from #AACR26; perspectives on #leukemia research from @DrHKantarjian; an interview with Matthew J. Ehrhardt, MD, MS; a law & ethics perspective from @GovindPersad; and MORE! ascopost.com/issues/may-10-…

🔬 Not all TP53-mutated DLBCL behaves the same Higher TP53 variant allele frequency (≥75%) linked to significantly worse outcomes, while R-CHOP + ibrutinib showed potential to overcome high-risk biology in trial analyses. 🔹 Uppal et al | @JCO_ASCO 🔗 ascopost.com/news/may-2026/…

🖥️ #ASCOAI: The @US_FDA is exploring how #AI could reshape early-phase clinical trials A new pilot program aims to use AI for real-time safety monitoring, dose selection, and faster regulatory decision-making to help accelerate drug development. Read more: ascoai.org/articles/2026/…